(Q38104742)

28 August 2017

title

Genes and beans: pharmacogenomics of renal transplant (English)

1 reference

28 August 2017

1 reference

Brian Murray

1

1 reference

28 August 2017

Emily Hawes

2

1 reference

28 August 2017

Ruth-Ann Lee

3

1 reference

28 August 2017

Robert Watson

4

1 reference

28 August 2017

Mary W Roederer

5

1 reference

28 August 2017

publication date

1 May 2013

1 reference

28 August 2017

1 reference

28 August 2017

volume

14

1 reference

28 August 2017

issue

7

1 reference

28 August 2017

page(s)

783-798

1 reference

Pharmacogenetics in solid organ transplantation: current status and future directions

28 August 2017

cites work

1 reference

Immunosuppressive drugs for kidney transplantation.

21 January 2018

1 reference

Adequate early cyclosporin exposure is critical to prevent renal allograft rejection: patients monitored by absorption profiling

21 January 2018

1 reference

The natural history of chronic allograft nephropathy

21 January 2018

1 reference

New-Onset Diabetes After Transplantation 2003 International Consensus Guidelines: an endocrinologist's view.

21 January 2018

1 reference

New insights into the pharmacokinetics and pharmacodynamics of the calcineurin inhibitors and mycophenolic acid: possible consequences for therapeutic drug monitoring in solid organ transplantation

21 January 2018

1 reference

Therapeutic drug monitoring of immunosuppressive drugs in kidney transplantation

21 January 2018

1 reference

Therapeutic drug monitoring of sirolimus for optimal renal transplant outcomes

21 January 2018

1 reference

Pharmacogenetics of immunosuppressive drugs: prospect of individual therapy for transplant patients

21 January 2018

1 reference

The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients

21 January 2018

1 reference

Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data

21 January 2018

1 reference

Review of major clinical trials with mycophenolate mofetil in cardiac transplantation

21 January 2018

1 reference

Mycophenolate mofetil decreases acute rejection and may improve graft survival in renal transplant recipients when compared with azathioprine: a systematic review

21 January 2018

1 reference

Mycophenolate mofetil reduces alveolar inflammation, acute rejection and graft loss due to bronchiolitis obliterans syndrome after lung transplantation

21 January 2018

1 reference

Long-term use of mycophenolate mofetil is associated with a reduction in the incidence and risk of late rejection

21 January 2018

1 reference

Azathioprine in liver transplantation: a reevaluation of its use and a comparison with mycophenolate mofetil

21 January 2018

1 reference

Mycophenolate mofetil versus azathioprine for prevention of acute rejection in renal transplantation (MYSS): a randomised trial

21 January 2018

1 reference

Mycophenolate mofetil versus azathioprine for prevention of chronic allograft dysfunction in renal transplantation: the MYSS follow-up randomized, controlled clinical trial.

21 January 2018

1 reference

Mycophenolate versus azathioprine for kidney transplantation: a 15-year follow-up of a randomized trial

21 January 2018

1 reference

Pharmacogenetics of calcineurin inhibitors in renal transplantation

21 January 2018

1 reference

Effects of genetic polymorphisms on the pharmacokinetics of calcineurin inhibitors

21 January 2018

1 reference

Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I.

21 January 2018

1 reference

Metabolism of tacrolimus (FK506) and recent topics in clinical pharmacokinetics

21 January 2018

1 reference

A Systematic Review of the Effect of CYP3A5 Genotype on the Apparent Oral Clearance of Tacrolimus in Renal Transplant Recipients

21 January 2018

1 reference

Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and P-glycoprotein correlate with dose requirement

21 January 2018

1 reference

The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation.

21 January 2018

1 reference

Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus

21 January 2018

1 reference

Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients.

21 January 2018

1 reference

Novel polymorphisms associated with tacrolimus trough concentrations: results from a multicenter kidney transplant consortium

21 January 2018

1 reference

CYP3A5 genotype is not associated with a higher risk of acute rejection in tacrolimus-treated renal transplant recipients.

21 January 2018

1 reference

Measurement and compartmental modeling of the effect of CYP3A5 gene variation on systemic and intrarenal tacrolimus disposition.

21 January 2018

1 reference

Using genetic and clinical factors to predict tacrolimus dose in renal transplant recipients

21 January 2018

1 reference

Dosing equation for tacrolimus using genetic variants and clinical factors

21 January 2018

1 reference

CYP3A4*22: promising newly identified CYP3A4 variant allele for personalizing pharmacotherapy

21 January 2018

1 reference

Tacrolimus population pharmacokinetic-pharmacogenetic analysis and Bayesian estimation in renal transplant recipients

21 January 2018

1 reference

NR1I2 polymorphisms are related to tacrolimus dose-adjusted exposure and BK viremia in adult kidney transplantation.

21 January 2018

1 reference

Donor ABCB1 variant associates with increased risk for kidney allograft failure

21 January 2018

1 reference

PPARA: a novel genetic determinant of CYP3A4 in vitro and in vivo

21 January 2018

1 reference

Influence of pharmacogenetic polymorphisms in routine immunosuppression therapy after renal transplantation.

21 January 2018

1 reference

Genetic polymorphisms and individualized tacrolimus dosing

21 January 2018

1 reference

CYP3A5 and ABCB1 polymorphisms influence tacrolimus concentrations in peripheral blood mononuclear cells after renal transplantation.

21 January 2018

1 reference

Influence of CYP3A5 and MDR1(ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in Chinese renal transplant recipients

21 January 2018

1 reference

The impact of pharmacogenomic factors on acute persistent rejection in adult lung transplant patients

21 January 2018

1 reference

Haplotypic structure of ABCB1/MDR1 gene modifies the risk of the acute allograft rejection in renal transplant recipients

21 January 2018

1 reference

Association of four DNA polymorphisms with acute rejection after kidney transplantation

21 January 2018

1 reference

Influence of ABCB1 polymorphisms and haplotypes on tacrolimus nephrotoxicity and dosage requirements in children with liver transplant.

21 January 2018

1 reference

Donor age and renal P-glycoprotein expression associate with chronic histological damage in renal allografts

21 January 2018

1 reference

Neurotoxicity induced by tacrolimus after liver transplantation: relation to genetic polymorphisms of the ABCB1 (MDR1) gene

21 January 2018

1 reference

The pharmacogenetics of calcineurin inhibitor-related nephrotoxicity

21 January 2018

1 reference

ATP-binding cassette transporters as pharmacogenetic biomarkers for kidney transplantation

21 January 2018

1 reference

KCNQ1 gene variants and risk of new-onset diabetes in tacrolimus-treated renal-transplanted patients.

21 January 2018

1 reference

The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients

21 January 2018

1 reference

Effects of genetic polymorphisms of CYP3A4, CYP3A5 and MDR1 on cyclosporine pharmacokinetics after renal transplantation.

21 January 2018

1 reference

The effect of variable CYP3A5 expression on cyclosporine dosing, blood pressure and long-term graft survival in renal transplant patients

21 January 2018

1 reference

Genetic polymorphisms of CYP3A5 genes and concentration of the cyclosporine and tacrolimus

21 January 2018

1 reference

Genetic polymorphisms in MDR1 and CYP3A4 genes in Asians and the influence of MDR1 haplotypes on cyclosporin disposition in heart transplant recipients

21 January 2018

1 reference

Explaining variability in ciclosporin exposure in adult kidney transplant recipients

21 January 2018

1 reference

Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the MDR-1, CYP3A4, and CYP3A5 genes.

21 January 2018

1 reference

Impact of CYP3A5 and CYP3A4 gene polymorphisms on dose requirement of calcineurin inhibitors, cyclosporine and tacrolimus, in renal allograft recipients of North India

21 January 2018

1 reference

ABCB1 G2677 allele is associated with high dose requirement of cyclosporin A to prevent renal allograft rejection in North India.

21 January 2018

1 reference

The effect of CYP3A5 and MDR1 polymorphic expression on cyclosporine oral disposition in renal transplant patients

21 January 2018

1 reference

Association between ABCB1 (multidrug resistance transporter) genotype and post-liver transplantation renal dysfunction in patients receiving calcineurin inhibitors.

21 January 2018

1 reference

ABCB1 genotypes predict cyclosporine-related adverse events and kidney allograft outcome

21 January 2018

1 reference

Donor P-gp polymorphisms strongly influence renal function and graft loss in a cohort of renal transplant recipients on cyclosporine therapy in a long-term follow-up.

21 January 2018

1 reference

ABCB1 genotype of the donor but not of the recipient is a major risk factor for cyclosporine-related nephrotoxicity after renal transplantation

21 January 2018

1 reference

Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials

21 January 2018

1 reference

Rapamycin in transplantation: a review of the evidence

21 January 2018

1 reference

Everolimus: a proliferation signal inhibitor with clinical applications in organ transplantation, oncology, and cardiology.

21 January 2018

1 reference

Sirolimus: continuing the evolution of transplant immunosuppression

21 January 2018

1 reference

Sirolimus population pharmacokinetic/pharmacogenetic analysis and bayesian modelling in kidney transplant recipients

21 January 2018

1 reference

CYP3A5*3 influences sirolimus oral clearance in de novo and stable renal transplant recipients.

21 January 2018

1 reference

The role of CYP3A5 genotypes in dose requirements of tacrolimus and everolimus after heart transplantation

21 January 2018

1 reference

The clinical pharmacology of 6-mercaptopurine

21 January 2018

1 reference

Selective inhibition of inflammatory gene expression in activated T lymphocytes: a mechanism of immune suppression by thiopurines

21 January 2018

1 reference

Thiopurine S-methyltransferase (TPMT) assessment prior to starting thiopurine drug treatment; a pharmacogenomic test whose time has come

21 January 2018

1 reference

Azathioprine pharmacokinetics after intravenous, oral, delayed release oral and rectal foam administration

21 January 2018

1 reference

Azathioprine metabolism: pharmacokinetics of 6-mercaptopurine, 6-thiouric acid and 6-thioguanine nucleotides in renal transplant patients

21 January 2018

1 reference

Cholestatic hepatocellular injury with azathioprine: a case report and review of the mechanisms of hepatotoxicity

21 January 2018

1 reference

Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing

21 January 2018

1 reference

Are patients with intermediate TPMT activity at increased risk of myelosuppression when taking thiopurine medications?

21 January 2018

1 reference

Thiopurine methyltransferase (TPMT) genotype distribution in azathioprine-tolerant and -intolerant patients with various disorders. The impact of TPMT genotyping in predicting toxicity

21 January 2018

1 reference

Thiopurine S-methyltransferase genotype predicts azathioprine-induced myelotoxicity in kidney transplant recipients.

21 January 2018

1 reference

TPMT genotype and its clinical implication in renal transplant recipients with azathioprine treatment.

21 January 2018

1 reference

Thiopurine S-methyltransferase gene polymorphism is predictive of azathioprine-induced myelosuppression in heart transplant recipients.

21 January 2018

1 reference

Thiopurine methyltransferase (TPMT) heterozygosity and enzyme activity as predictive tests for the development of azathioprine-related adverse events.

21 January 2018

1 reference

Thiopurine methyltransferase activity and its relationship to the occurrence of rejection episodes in paediatric renal transplant recipients treated with azathioprine

21 January 2018

1 reference

The design and development of an immunosuppressive drug, mycophenolate mofetil

21 January 2018

1 reference

The kinetics of mycophenolic acid and its glucuronide metabolite in adult kidney transplant recipients

21 January 2018

1 reference

Pharmacokinetics of mycophenolic acid in renal insufficiency

21 January 2018

1 reference

Genetic determinants of mycophenolate-related anemia and leukopenia after transplantation

21 January 2018

1 reference

Global analysis of genetic variation in SLCO1B1.

21 January 2018

1 reference

SLCO1B1 genetic polymorphism influences mycophenolic acid tolerance in renal transplant recipients

21 January 2018

1 reference

Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients

21 January 2018

1 reference

The role of organic anion-transporting polypeptides and their common genetic variants in mycophenolic acid pharmacokinetics.

21 January 2018

1 reference

Mycophenolic acid-related diarrhea is not associated with polymorphisms in SLCO1B nor with ABCB1 in renal transplant recipients.

21 January 2018

1 reference

Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein 2.

21 January 2018

1 reference

Cyclosporin A, but not tacrolimus, inhibits the biliary excretion of mycophenolic acid glucuronide possibly mediated by multidrug resistance-associated protein 2 in rats

21 January 2018

1 reference

Role of Mrp2 in the hepatic disposition of mycophenolic acid and its glucuronide metabolites: effect of cyclosporine

21 January 2018

1 reference

The prevalence of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T and its influence on mycophenolic acid pharmacokinetics in stable renal transplant patients.

21 January 2018

1 reference

The impact of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T on early mycophenolic acid dose-interval exposure in de novo renal allograft recipients

21 January 2018

1 reference

Current target ranges of mycophenolic acid exposure and drug-related adverse events: a 5-year, open-label, prospective, clinical follow-up study in renal allograft recipients.

21 January 2018

1 reference

UGT1A9 -275T>A/-2152C>T polymorphisms correlate with low MPA exposure and acute rejection in MMF/tacrolimus-treated kidney transplant patients

21 January 2018

1 reference

Pharmacogenetic effect of the UGT polymorphisms on mycophenolate is modified by calcineurin inhibitors

21 January 2018

1 reference

Therapeutic drug monitoring of mycophenolate mofetil in transplantation

21 January 2018

1 reference

Risk of diarrhoea in a long-term cohort of renal transplant patients given mycophenolate mofetil: the significant role of the UGT1A8 2 variant allele

21 January 2018

1 reference

Influence of uridine diphosphate (UDP)-glucuronosyltransferases and ABCC2 genetic polymorphisms on the pharmacokinetics of mycophenolic acid and its metabolites in Chinese renal transplant recipients

21 January 2018

1 reference

C-440T/T-331C polymorphisms in the UGT1A9 gene affect the pharmacokinetics of mycophenolic acid in kidney transplantation

21 January 2018

1 reference

Genetic polymorphisms of MRP2 and UGT2B7 and gastrointestinal symptoms in renal transplant recipients taking mycophenolic acid

21 January 2018

1 reference

Pharmacogenetic influences on mycophenolate therapy

21 January 2018

1 reference

IMPDH1 gene polymorphisms and association with acute rejection in renal transplant patients

21 January 2018

1 reference

Interpatient variability in IMPDH activity in MMF-treated renal transplant patients is correlated with IMPDH type II 3757T > C polymorphism

21 January 2018

1 reference

Effect of a new functionalCYP3A4polymorphism on calcineurin inhibitors’ dose requirements and trough blood levels in stable renal transplant patients

21 January 2018

1 reference

Pharmacogenetics of calcineurin inhibitors in Brazilian renal transplant patients

21 January 2018

1 reference

Association of CYP3A4*18B polymorphisms with the pharmacokinetics of cyclosporine in healthy subjects

21 January 2018

1 reference

Azathioprine toxicity and thiopurine methyltransferase genotype in renal transplant patients

21 January 2018

1 reference

Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method

21 January 2018

1 reference

The influence of CYP3A gene polymorphisms on cyclosporine dose requirement in renal allograft recipients

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.2217/PGS.13.68

1 reference

28 August 2017

1 reference